Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bispecific antibodies in cancer therapy: Target selection and regulatory requirements
Yanze Sun, Xinmiao Yu, Xiao Wang, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 9, pp. 3583-3597
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Bispecific and multispecific antibodies in oncology: opportunities and challenges
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 37
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
Man Wang, Fei Yu, Yuan Zhang
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 8
Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy
Rose Ghemrawi, Lama Abuamer, Sedra Kremesh, et al.
Biomedicines (2024) Vol. 12, Iss. 9, pp. 2158-2158
Open Access | Times Cited: 12
Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells
Agnieszka Dąbkowska, Krzysztof Domka, Małgorzata Firczuk
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 9
Investigation and Elimination of Noncovalent Artificial Aggregates during Non-Reduced Capillary Electrophoresis-Sodium Dodecyl Sulfate Analysis of a Multi-Specific Antibody
Jianhui Cheng, Q. Lv, Yibing Ji, et al.
Journal of Pharmaceutical and Biomedical Analysis (2025) Vol. 255, pp. 116673-116673
Closed Access | Times Cited: 1
Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for Cancer Immunotherapy
Qiaohong Geng, Peifu Jiao
Molecules (2024) Vol. 29, Iss. 2, pp. 454-454
Open Access | Times Cited: 8
Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy
Xiaojing Qin, Wenjing Ning, Han Liu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2361-2377
Open Access | Times Cited: 8
Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
Khubaib Ali, Muhammad Nabeel, Fatima Mohsin, et al.
Medical Oncology (2024) Vol. 41, Iss. 5
Closed Access | Times Cited: 5
Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges
A. Raja, Abhishek Kasana, Vaishali Verma
Molecular Biotechnology (2024)
Closed Access | Times Cited: 5
Unlocking the potential of bispecific ADCs for targeted cancer therapy
Hongye Zeng, Wenjing Ning, Xue Liu, et al.
Frontiers of Medicine (2024) Vol. 18, Iss. 4, pp. 597-621
Closed Access | Times Cited: 4
Formation of mono- and dual-labelled antibody fragment conjugates via reversible site-selective disulfide modification and proximity induced lysine reactivity
Ioanna A. Thanasi, Nathalie Bouloc, Clíona McMahon, et al.
Chemical Science (2025)
Open Access
Bispecific antibodies and CLEM: an analytical approach to advanced cell imaging for therapeutic strategies
Han‐ul Kim, Young Kwan Kim
Han-guk hyeonmigyeong hakoeji/Applied microscopy (2025) Vol. 55, Iss. 1
Open Access
Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
Masaud Shah, Muhammad Hussain, Hyun Goo Woo
Genomics & Informatics (2025) Vol. 23, Iss. 1
Open Access
NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption
Nerea Sánchez-Gaona, David Perea, Adrián Curran, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
Exploring the potential of bi-specific antibodies in cancer immunotherapy
Kirolos Eskandar
Surgery and Oncology (2025) Vol. 15, Iss. 1, pp. 11-17
Closed Access
Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment
Weijiao Chen, Xujie Zhuang, Yuanyuan Chen, et al.
Chinese Journal of Natural Medicines (2025) Vol. 23, Iss. 3, pp. 286-298
Closed Access
A pilot study to determine the feasibility and safety of pharmacist and nurse driven management of venetoclax ramp-up in patients with chronic lymphocytic leukemia
Rachel J. Bubik, Monica I. Aasum, Linda M. Tamminga, et al.
Journal of Oncology Pharmacy Practice (2025)
Closed Access
Diferenciación, activación y clasificación de los linfocitos B
R. Sánchez Martín, A. Miranda, J. Monserrat Sanz, et al.
Medicine - Programa de Formación Médica Continuada Acreditado (2025) Vol. 14, Iss. 28, pp. 1660-1672
Closed Access
Dual-filler mixed matrix membrane with covalent-organic framework and nano TiO2/polyether sulfone for efficient antibody purification
Zhenhui Liu, Peijun Ye, Leying Shi, et al.
Journal of Chromatography A (2025) Vol. 1751, pp. 465940-465940
Closed Access
Affinity Resin Selection for Efficient Capture of Bispecific Antibodies as Guided by Domain Composition
Nattha Ingavat, Xinhui Wang, Yee Jiun Kok, et al.
Process Biochemistry (2025)
Closed Access
The Role of Monoclonal Antibodies as Therapeutics in HPV-Related Head and Neck Cancers: An Updated Review
Michael Zalin, Shaan Patel, Christiana Coggins, et al.
Antibodies (2025) Vol. 14, Iss. 2, pp. 37-37
Open Access
Bispecific Antibodies, Nanobodies and Extracellular Vesicles: Present and Future to Cancer Target Therapy
Asier Lizama-Muñoz, Julio Plaza‐Díaz
Biomolecules (2025) Vol. 15, Iss. 5, pp. 639-639
Open Access
Therapeutic potential of cis-targeting bispecific antibodies
Rob Oslund, Pamela M. Holland, Scott A. Lesley, et al.
Cell chemical biology (2024) Vol. 31, Iss. 8, pp. 1473-1489
Closed Access | Times Cited: 3
Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors
Ravit Geva, María Vieito, Jorge Ramón, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 10
Open Access | Times Cited: 3
Therapeutic antibodies in oncology: an immunopharmacological overview
Karen Toledo‐Stuardo, Carolina Ribeiro, Fabiola González‐Herrera, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 12
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top